Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.

The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.

A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.

GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

A user is seeking recommendations for a dermatologist in Houston specializing in alopecia areata for her daughter. A doctor actively researching alopecia areata in young people was suggested.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

19-year-old with Lichen Planopilaris tried various treatments unsuccessfully. Now considering hair systems, seeking experiences and opinions.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.